BioXcel Therapeutics (NASDAQ:BTAI) Reaches New 1-Year Low at $18.33

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $18.33 and last traded at $18.40, with a volume of 2824 shares. The stock had previously closed at $19.45.

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $141.00 price target on shares of BioXcel Therapeutics in a report on Tuesday, October 19th. The Goldman Sachs Group lowered shares of BioXcel Therapeutics from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $55.00 to $24.00 in a report on Monday, November 15th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $97.29.

The company’s fifty day moving average is $23.68 and its 200 day moving average is $26.75. The company has a market cap of $516.51 million, a P/E ratio of -4.49 and a beta of 0.97.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, November 9th. The company reported ($0.96) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.08) by $0.12. During the same quarter in the prior year, the business posted ($1.07) EPS. On average, sell-side analysts forecast that BioXcel Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of BioXcel Therapeutics by 39.7% during the 2nd quarter. FMR LLC now owns 3,114,813 shares of the company’s stock valued at $90,516,000 after purchasing an additional 884,970 shares during the last quarter. State Street Corp grew its holdings in shares of BioXcel Therapeutics by 14.4% during the 2nd quarter. State Street Corp now owns 1,459,115 shares of the company’s stock valued at $42,402,000 after purchasing an additional 183,209 shares during the last quarter. BlackRock Inc. grew its holdings in shares of BioXcel Therapeutics by 7.4% during the 3rd quarter. BlackRock Inc. now owns 1,216,737 shares of the company’s stock valued at $36,928,000 after purchasing an additional 84,335 shares during the last quarter. Alliancebernstein L.P. boosted its position in BioXcel Therapeutics by 8.2% during the 3rd quarter. Alliancebernstein L.P. now owns 1,020,255 shares of the company’s stock valued at $30,965,000 after buying an additional 76,995 shares during the period. Finally, Vanguard Group Inc. boosted its position in BioXcel Therapeutics by 14.3% during the 2nd quarter. Vanguard Group Inc. now owns 902,646 shares of the company’s stock valued at $26,231,000 after buying an additional 113,207 shares during the period. 45.59% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Company Profile (NASDAQ:BTAI)

BioXcel Therapeutics, Inc is a clinical stage biopharmaceutical company, which focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Recommended Story: Breakout Stocks

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.